|Study Period:||2018 - 2026|
Need a report that reflects how COVID-19 has impacted this market and its growth?
India In-vitro diagnostics market estimated to be valued at USD USD 1255.18 million in 2020 and is expected to reach approximately USD 1990.99 million in 2026, registering a CAGR of nearly 7.10% during the forecast period.
In the context of COVID-19, government organizations in various countries, research institutes, and many global and domestic companies are focusing on the launch of new products, which may contribute to the growth of the market studied. For instance, in July 2020, the Indian Institute of Technology (IIT), Delhi, launched a COVID-19 test kit and approved by the Indian Council of Medical Research (ICMR). In September 2020, the Central Drugs Standard Control Organization (CDSCO), which regulates pharmaceuticals and medical devices in India, approved the manufacture and sale of ‘CoViDx One,’ an RT-PCR test kit developed by Pune-based GenePath Diagnostics.
The major factors that are driving the growth of the Indian in-vitro diagnostics market are the high prevalence of chronic diseases, increasing use of point-of-care (POC) diagnostics, and rising awareness and acceptance of personalized medicine and companion diagnostics. According to the GLOBOCAN factsheet, in 2020, the number of prevalent cancer cases in five years was found to be 2,720,251 among all age groups in India. Additionally, as per the International Agency for Research on Cancer (IARC), the incident cases in India are estimated to rise from 1.15 million in 2018 to 1.9 million in 2040. Similarly, according to the National Diabetes and Diabetic Retinopathy Survey report 2015-2019, there are 11.8% prevalent cases of diabetes in India. As diabetic is a major risk factor for many diseases it is expected to have significant growth of the market over the forecast period.
Furthermore, emerging technological innovations in healthcare, such as bio-sensors, lab-on-a-chip, wearable devices, and POC diagnostics, are increasingly becoming an important part of the healthcare landscape. POC testing helps bring testing closer to the patients and obtain results quickly for the healthcare provider to expedite diagnoses and subsequent treatment. This is likely to increase the adoption of in-vitro diagnostics in India.
However, stringent regulatory policies and lack of sufficient reimbursement policies are projected to hamper the market growth of in-vitro diagnostics market over forecast period.
Scope of the Report
As per the scope of the report, The in vitro diagnostics market is inclusive of all medical devices and consumables that are utilized to perform in vitro tests on various biological samples, used for the diagnosis of various medical conditions, such as chronic diseases. The market is segmented by test type into clinical chemistry, molecular diagnostics, immunodiagnostics, haematology, and other test types, by product into, instruments, reagents, and other products, by usability into disposable IVD devices and reusable IVD devices, by application into, infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications, and by end-user into diagnostic laboratories, hospitals and clinics, and other end users. The report offers the value (in USD million) for the above segments.
|By Test Type|
|Disposable IVD Devices|
|Reusable IVD Devices|
|By End User|
|Hospitals & Clinics|
|Other End Users|
Key Market Trends
Molecular Diagnostics Segment is Expected to Grow with CAGR of 7.12% Over the Forecast Period
Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging.
Factors, such as large outbreaks of bacterial and viral epidemics in India, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment. Also, advancements in molecular diagnostics and new product launches in India projected to boost the segment growth over the forecast period. For instance, in January 2020, CO-Diagnostics, Inc. and Cosara have launched CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus.
Moreover, with the advent of COVID 19, many of the companies are focused on developing effective molecular diagnostics for the disease. In March 2020, Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd, had received the license from the Central Drugs Standards Control Organization (CDSCO) to manufacture RT-PCR COVID-19 test kits. Similarly, Mylab Discovery Solutions, which is a Pune-based molecular diagnostics company, launched ist Compact XL to automate the manual processes of molecular diagnostic tests, such as RT-PCR tests for COVID-19.
The technological advancements in this segment have been significant, and the cost of these molecular diagnostic tests have decreased steadily, to make them accessible to more patients suffering from genetic diseases and infectious diseases. Additionally, the outbreak of COVID-19 in the region has increased the demand for molecular diagnostics, which is boosting market growth.
To understand key trends, Download Sample Report
The market studied is consolidated with the presence of a few major players. For the new entrants in the market, the barriers are high in this industry, and hence, few major market players hold the maximum market share. Some of the market players are Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Qiagen NV, and Thermo Fisher Scientific. Companies are adopting various strategies such as collaborations, acquisitions, new launches to expand market position. For instance, in February 2018, Fujifilm Corp announced its foray into India’s fragmented diagnostics market with the launch of a medical screening centre focusing on cancer screening in Bengaluru in collaboration with Dr Kutty’s Healthcare.
Becton, Dickinson and Company
F. Hoffmann-La Roche AG
Transasia Bio-Medicals Ltd
Thermo Fisher Scientific
- In February 2021, Thermo Fisher Scientific Inc. set up a new state-of-the-art manufacturing facility in Bengaluru to produce COVID-19 testing kits and diagnostic solutions.
- In September 2020, in collaboration with the Center for Cellular and Molecular Platforms and the Bangalore Life Science Cluster, the Indigenization of Diagnostics (InDx) was planning to build a robust supply chain network of Indian small and medium enterprises capable of the production of reagents.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Rising Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.4 Immuno Diagnostics
5.1.5 Other Types
5.2 By Product
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.5 Autoimmune Disease
5.4.7 Other Applications
5.5 By End User
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals & Clinics
5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Arkray Inc.
6.1.3 Becton, Dickinson and Company
6.1.4 bioMérieux SA
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Danaher Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Transasia Bio-Medicals Ltd
6.1.9 Sysmex Corporation
6.1.10 Thermo Fisher Scientific
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The India In-Vitro Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of India In-Vitro Diagnostics Market?
The India In-Vitro Diagnostics Market is growing at a CAGR of 7.1% over the next 5 years.
What is India In-Vitro Diagnostics Market size in 2018?
The India In-Vitro Diagnostics Market is valued at 1255 Million USD in 2018.
What is India In-Vitro Diagnostics Market size in 2026?
The India In-Vitro Diagnostics Market is valued at 1990 Million USD in 2026.
Who are the key players in India In-Vitro Diagnostics Market?
Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Transasia Bio-Medicals Ltd, Thermo Fisher Scientific are the major companies operating in India In-Vitro Diagnostics Market.